ATE92531T1 - Rekombinante herpes simplex-viren, vakzine und verfahren. - Google Patents

Rekombinante herpes simplex-viren, vakzine und verfahren.

Info

Publication number
ATE92531T1
ATE92531T1 AT87303512T AT87303512T ATE92531T1 AT E92531 T1 ATE92531 T1 AT E92531T1 AT 87303512 T AT87303512 T AT 87303512T AT 87303512 T AT87303512 T AT 87303512T AT E92531 T1 ATE92531 T1 AT E92531T1
Authority
AT
Austria
Prior art keywords
vaccines
methods
hsv
viruses
herpes simplex
Prior art date
Application number
AT87303512T
Other languages
English (en)
Inventor
Bernard Roizman
Original Assignee
Arch Dev Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Dev Corp filed Critical Arch Dev Corp
Application granted granted Critical
Publication of ATE92531T1 publication Critical patent/ATE92531T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT87303512T 1986-04-25 1987-04-22 Rekombinante herpes simplex-viren, vakzine und verfahren. ATE92531T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/856,052 US4859587A (en) 1984-06-04 1986-04-25 Recombinant herpes simplex viruses, vaccines and methods
EP87303512A EP0243155B1 (de) 1986-04-25 1987-04-22 Rekombinante Herpes simplex-Viren, Vakzine und Verfahren

Publications (1)

Publication Number Publication Date
ATE92531T1 true ATE92531T1 (de) 1993-08-15

Family

ID=25322756

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87303512T ATE92531T1 (de) 1986-04-25 1987-04-22 Rekombinante herpes simplex-viren, vakzine und verfahren.

Country Status (9)

Country Link
US (1) US4859587A (de)
EP (1) EP0243155B1 (de)
JP (1) JPH084497B2 (de)
AT (1) ATE92531T1 (de)
AU (1) AU585126B2 (de)
CA (1) CA1305081C (de)
DE (1) DE3786824T2 (de)
ES (1) ES2059370T3 (de)
ZA (1) ZA87818B (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264817B1 (en) 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5965138A (en) * 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
IE61575B1 (en) * 1987-05-04 1994-11-16 Merck & Co Inc A stable lyophilized live herpes virus vaccine
US5633152A (en) * 1988-06-24 1997-05-27 Carnegie Institution Of Washington Method of controlling viral growth
GB8918616D0 (en) * 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
ES2070997T3 (es) * 1989-12-04 1995-06-16 Akzo Nobel Nv Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos.
CA2088600C (en) * 1990-08-02 1999-11-16 Rae L. Burke Herpes simplex virus vp16 vaccines
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US5849571A (en) * 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US5849572A (en) * 1990-10-10 1998-12-15 Regents Of The University Of Michigan HSV-1 vector containing a lat promoter
GB9102126D0 (en) * 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
US6040169A (en) * 1991-01-31 2000-03-21 Medical Research Council Herpes simplex virus-1 deletion variants and vaccines thereof
WO1993004169A1 (en) * 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5679348A (en) * 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
US6022726A (en) * 1992-02-03 2000-02-08 Palese; Peter Genetically engineered attenuated viruses
CA2090295A1 (en) * 1992-02-03 1993-08-04 Anthony B. Nesburn Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use
US5955088A (en) * 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
US5672349A (en) * 1992-02-03 1997-09-30 Cedars Sinai Medical Center Process for the expression of herpes simplex virus type 1 glycoprotein I and methods of use
US6193984B1 (en) 1992-02-03 2001-02-27 Cedars-Sinai Medical Center Pharmaceutical composition of herpes simplex virus typ-1 (HSV-1) glycoproteins
ES2183811T3 (es) * 1992-03-31 2003-04-01 Arch Dev Corp Tratamiento de enfermedades tumorigenas con un hsv modificado.
US6316243B1 (en) 1992-04-14 2001-11-13 Peter Palese Genetically engineered attenuated double-stranded RNA viruses
US6183753B1 (en) * 1994-08-09 2001-02-06 Schering-Plough Veterinary Corp. Recombinant chimeric virus and uses thereof
TW289731B (de) * 1992-07-09 1996-11-01 Akzo Nv
US7223411B1 (en) 1992-07-31 2007-05-29 Dana-Farber Cancer Institute Herpesvirus replication defective mutants
CA2141574C (en) * 1992-07-31 2009-11-24 David Knipe Herpesvirus vaccines
ES2191681T3 (es) * 1992-12-23 2003-09-16 Arch Dev Corp Promotores sinteticos de virus de herpes simple.
CA2158935A1 (en) * 1993-10-12 1995-04-20 Chiron Viagene, Inc. Methods for preserving recombinant viruses
US5763217A (en) * 1993-11-10 1998-06-09 University Of British Columbia Method of using, process of preparing and composition comprising recombinant herpesvirus vectors
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
FR2728795B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
FR2728794B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
KR100408817B1 (ko) * 1995-07-28 2004-02-25 주식회사 엘지생명과학 헤르페스심플렉스바이러스의당단백질을대량발현시키는동물세포주
US5834216A (en) * 1995-09-06 1998-11-10 Arch Development Corporation Screening methods for the identification of inducers and inhibitors of programmed cell death (apoptosis)
ATE241994T1 (de) * 1996-01-25 2003-06-15 Univ Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
GB9615794D0 (en) 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
EP1025212B1 (de) 1997-10-14 2007-09-26 Darwin Molecular Corporation Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten
US6399354B1 (en) 1998-07-31 2002-06-04 President And Fellows Of Harvard College Replication-competent virus expressing a detectable fusion protein
IL141044A0 (en) * 1998-08-07 2002-02-10 Univ Washington Innunological herpes simplex virus antigens and methods for use thereof
EP1141338A4 (de) * 1998-12-31 2002-09-25 Arch Dev Corp Rekombinantes herpes simplex virus zur behandlung von neoplastischen erkrankungen
ES2263454T3 (es) 1999-02-05 2006-12-16 Arch Development Corporation Virus herpes modificado geneticamente para el tratamiento de tumores.
US6774119B1 (en) * 1999-04-26 2004-08-10 Cedars-Sinai Medical Center Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells
DE60045931D1 (de) 1999-07-07 2011-06-16 Zymogenetics Inc Menschliches Rezeptor für Zytokine
AU782676B2 (en) 1999-09-30 2005-08-18 Corixa Corporation Immunologically significant herpes simplex virus antigens
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US6516246B2 (en) * 2000-09-11 2003-02-04 Mimicking Man Manually, Inc. Method and system for determining native neurological dominant hemisphere
WO2002045431A2 (en) 2000-11-28 2002-06-06 The University Of Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
EA010594B1 (ru) 2001-05-24 2008-10-30 Займодженетикс, Инк. Слитые белки taci-иммуноглобулина
WO2003011893A2 (en) * 2001-07-31 2003-02-13 University Of Washington Immunologically significant herpes simplex virus antigens and methods for using same
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
RU2225223C1 (ru) * 2002-06-14 2004-03-10 Закрытое акционерное общество Фирма "ВИТАФАРМА" Лиофилизированная антигерпетическая вакцина
AU2003252052A1 (en) * 2002-07-18 2004-02-09 University Of Washington Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same
US20050069929A1 (en) 2003-08-08 2005-03-31 Invitrogen Corporation Methods and compositions for seamless cloning of nucleic acid molecules
US8304189B2 (en) 2003-12-01 2012-11-06 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same
US7731952B2 (en) 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
US20100008944A1 (en) * 2005-07-29 2010-01-14 President And Fellows Of Harvard College Herpes simplex virus mutant and uses therefore
US8460674B2 (en) * 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
WO2010115172A2 (en) 2009-04-03 2010-10-07 University Of Washington Antigenic peptide of hsv-2 and methods for using same
CA2847057C (en) 2011-08-31 2019-06-11 St. Jude Children's Research Hospital Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use
HK1209430A1 (en) 2012-04-24 2016-04-01 迈阿密大学 Perforin 2 defense against invasive and multidrug resistant pathogens
JP2016534152A (ja) 2013-10-09 2016-11-04 ユニバーシティ オブ マイアミ 感染性疾患及び腸の炎症の薬剤標的としてのパーフォリン−２活性化剤及び阻害剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769331A (en) * 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
EP0074808A3 (de) * 1981-09-16 1984-07-04 University Patents, Inc. Rekombinantes Verfahren und Materialien
US4554159A (en) * 1981-11-12 1985-11-19 Institute Merieux Vaccine and method of immunizing against herpes simplex virus (types 1 and 2)
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
GB8305323D0 (en) * 1983-02-25 1983-03-30 Baylor College Medicine Infectious bovine rhinotracheitis vaccine
DE3461928D1 (en) * 1983-06-23 1987-02-12 Person Stanley Immunologically reactive non-glycosylated amino acid chains of glycoprotein b of herpes virus types 1 and 2
NL8303501A (nl) * 1983-10-12 1985-05-01 Centraal Diergeneeskundig Inst Deletiemutant van een herpesvirus en vaccin, dat dit virus bevat.
CA1282721C (en) * 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
EP0256092B1 (de) * 1986-01-27 1998-04-08 Syntro Corporation Abgeschwächte herpesviren, herpesviren, die eine für aminosäuresequenzen kodierende fremd-dns enthalten, sowie impfstoffe, die diese enthalten

Also Published As

Publication number Publication date
DE3786824D1 (de) 1993-09-09
EP0243155B1 (de) 1993-08-04
EP0243155A2 (de) 1987-10-28
AU585126B2 (en) 1989-06-08
DE3786824T2 (de) 1994-01-20
EP0243155A3 (en) 1989-07-26
US4859587A (en) 1989-08-22
AU6861487A (en) 1987-10-29
JPS62257385A (ja) 1987-11-09
ZA87818B (en) 1987-12-30
ES2059370T3 (es) 1994-11-16
JPH084497B2 (ja) 1996-01-24
CA1305081C (en) 1992-07-14

Similar Documents

Publication Publication Date Title
DE3786824D1 (de) Rekombinante herpes simplex-viren, vakzine und verfahren.
PH25776A (en) Pseudorabies virus mutants incapable of producing glycoprotein x
EP0500917A4 (en) Recombinant herpes simplex viruses vaccines and methods
MX9700833A (es) Virus de herpes recombinante de pavo y usos del mismo.
AU6489986A (en) Thymidine kinase deletion mutants of bovine herpersvirus-1, vaccines against infectious bovine rhinotracheitis containing same and methods for the production and use of same
EP0232798A3 (de) Pseudorabies-Virus-Mutanten, diese enthaltende Vakzine, Verfahren zu deren Herstellung sowie Methoden für deren Anwendung
UA40571C2 (uk) Мутант коров'ячого вірусу герпесу типу 1 (bhv-1), композиція вакцини для вакцинації тварин для захисту їх від bhv-1, композиція вакцини для вакцинації тварин для захисту їх від патогена
EP0261940A3 (de) Pseudorabies-Impfstoffe und DNS-Vektoren zur Rekombination mit Poxviren
EP0507179A3 (en) Equine herpes viruses (ehv) containing foreign dna, process for their preparation and their use as vaccines
AU2403188A (en) Infectious bovine rhinotracheitis virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
AU4334193A (en) Infectious bovine rhinotracheitis virus mutants and vaccines
GR3007856T3 (de)
DK0606452T3 (da) Vektorvacciner fra rekombinant katteherpesvirus
ATE244308T1 (de) Rekombitante, equine herpesviren
NZ220645A (en) Modified varicella-zoster virus and its cultivation
EA200100720A1 (ru) Вирусная вакцина на основе делеционного вируса герпеса крупного рогатого скота типа 1 (bhv-1)
EP0668356A3 (de) Rekombinante, infektöse Rinder-Rhinotracheitis-Mutante, Methode zu deren Herstellung, und Vakzine dieselbige enthaltend

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time